Business Wire

Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery

Jaa

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1

In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and central venous pressure (CVP) measured via a central venous access catheter as indicators of fluid responsiveness. The GDFT group’s fluid status was monitored using a GDFT protocol based on PVi as a noninvasive, dynamic indicator of fluid responsiveness.

Both groups were initially administered 500 mL bolus colloid fluid at the beginning of surgery, followed by a continuous infusion of crystalloid fluid (4-8 mL/kg/h in the control group, or 2 mL/kg/h in the GDFT group per the protocol). In the control group, if CVP was less than 6 mmHg or MAP less than 65 mmHg, a 250 mL additional bolus of colloid fluid was administered. In the GDFT group, if PVi was greater than 14% for five minutes, the 250 mL colloid bolus was administered.

The researchers found that there was a significantly higher mean volume of crystalloid fluid administered in the control group (1499 mL ± 516.87 mL) compared to the GDFT group (1126 mL ± 234.98 mL) (p = 0.001). There were no significant differences in blood lactate levels (p > 0.05) or creatinine levels before and after surgery (p > 0.05) between the two groups.

The researchers concluded that, “Utilization of GDFT protocols based on PVi may prevent excessive intraoperative infusion of fluids in laparoscopic bariatric surgery. This method when intending to prevent intraoperative excessive fluid loading in RYGB surgery appears to have no effect on either renal functions or lactate levels. While this study shows the adequacy of PVi for fluid therapy in mechanically ventilated patients undergoing bariatric surgery, further research is warranted to assess adequacy of optimization of PVi.”

@MasimoInnovates | #Masimo

Reference

  1. Demirel I, Bolat E, Altun AY, Özdemir M, and Beştaş A. Efficacy of Goal-Directed Fluid Therapy via Pleth Variability Index During Laparoscopic Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients. Obes Surg. 31 July 2017. DOI: 10.1007/s11695-017-2840-1.

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,1 improve CCHD screening in newborns,2 and, when used for continuous monitoring with Masimo Patient SafetyNet™* in post-surgical wards, reduce rapid response activations and costs.3,4,5 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,6 and is the primary pulse oximetry at 16 of the top 20 hospitals listed in the 2016-17 U.S. News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), and more recently, Oxygen Reserve Index (ORi™), in addition to SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor, iSpO2 ® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.

ORi has not received FDA 510(k) clearance and is not available for sale in the United States.

*The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  2. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;338.
  3. Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
  4. Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  5. McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  6. Estimate: Masimo data on file.
  7. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo PVi®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo PVi, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Contact information

Masimo
Evan Lamb
949-396-3376
elamb@masimo.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Brooks Levitate with DNA AMP Delivers Infinite Energy20.9.2017 07:01Tiedote

Based on seven years of Run Signature research, Brooks Running is launching the all new Levitate with DNA AMP—a shoe engineered to provide the most energy return of leading performance running shoes. The springy and responsive Brooks Levitate is available for pre-order beginning today at http://www.brooksrunning.com/en_us/brooks-levitate-running-shoes.html and will be available worldwide Sept. 30. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170919006747/en/ Brooks Levitate with DNA AMP Delivers Infinite Energy (Photo: Business Wire) “We’re pushing the limits of energy return with the new Brooks Levitate and are excited to unveil a shoe that has been engineered from the ground up to provide runners with an infinitely energetic experience,” said Carson Caprara, director of global product line ma

Ipsen Receives Approval from European Commission for Xermelo® (Telotristat Ethyl) for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy19.9.2017 19:00Tiedote

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced that the European Commission has approved Xermelo® (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. This approval allows for the marketing of Xermelo® (telotristat ethyl) in the above indication in all 28 member states of the European Union, Norway and Iceland. David Meek, Chief Executive Officer, Ipsen stated: “We are delighted to provide patients suffering from inadequately controlled carcinoid syndrome with a new treatment option in combination with a somatostatin analogue that demonstrates both efficacy and safety in particularly improving diarrhea, a most debilitating symptom. Xe

6th Annual World Patient Safety, Science & Technology Summit to Be Held in London, England19.9.2017 18:00Tiedote

The Patient Safety Movement Foundation (PSMF) announces that the 6th Annual World Patient Safety, Science & Technology Summit will take place in London on February 23-25, 2018. Rt. Hon. Jeremy Hunt MP, the Secretary of State for Health from England’s Department of Health, invited PSMF to hold its 6th annual Summit in London during his speech at the Summit in February of this year. This is the first time the Summit will be held outside of the United States. Over the years, the PSMF has taken an increasingly international scope to reach zero preventable patient deaths by 2020. They currently have over 30 Regional Chapters around the world and partnerships with global organizations such as the World Federation of Societies of Anaesthesiologists (WFSA), European Society of Anaesthesiology (ESA), Global Sepsis Alliance (GSA), the Taiwan Patient Safety Culture Club, Sistema Españo

Vertex Announces Upcoming Presentations of Data at 2017 North American Cystic Fibrosis Conference19.9.2017 17:50Tiedote

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its cystic fibrosis (CF) research and development program will be presented at the annual North American Cystic Fibrosis Conference (NACFC) in Indianapolis, November 2 to 4, 2017. Previously announced data from the Phase 3 EVOLVE and EXPAND studies of the investigational tezacaftor/ivacaftor combination in people with CF ages 12 and older who have certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene will be presented for the first time. Additionally, data from the Phase 3 extension study of ORKAMBI® (lumacaftor/ivacaftor) in children with CF ages 6 to 11 who have two copies of the F508del mutation and real-world KALYDECO® (ivacaftor) data will be presented. The company also submitted an abstract for the late-breaking poster session with previously announced Phase 1

Biker Summer 2017 campaign: Last Chance to Win Great Prizes from Moto-tyres.co.uk19.9.2017 16:57Tiedote

Moto-tyres.co.uk wants to know: For the fifth year in a row, the online motorbike shop is asking bikers from ten European countries about their Biker Summer 2017 travel plans, favourite destinations and longest tours. For survey participants, Moto-tyres.co.uk and its sister shops in other European countries are raffling prizes to get every biker’s heart beating faster, including vouchers for new motorbike tyres, a GARMIN motorbike GPS navigation system, and a GoPro camera with helmet attachment. For more information and a link to the survey, go to: www.moto-tyres.co.uk/promotion-biker-summer-2017.html. The Biker Summer 2017 campaign is running until 30th September 2017 – so you still have time to join in and win top-quality equipment for your next bike tour. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170919006105/en/

Andersen Global Expands into Uruguay19.9.2017 16:30Tiedote

Andersen Global announces its expansion into Uruguay through a Collaboration Agreement with Fischer & Schickendantz, one of the country’s leading law firms. The addition of Fischer & Schickendantz continues Andersen Global’s expansion and robust presence within the Latin American region. The team is led by Managing Partner, Juan Federico Fischer. “The addition of Juan Federico and the individuals at Fischer & Schickendantz bring a new depth to our team and our business development efforts in South America, while allowing us to deliver additional services in the region,” said Andersen Tax CEO, Mark Vorsatz. “Uruguay is the next major step in our firm’s growth and is an excellent complement for Andersen Global. The ability to provide a full scope of services in Uruguay offers significant advantages, especially given their large cross border client base and Uruguay’s increase

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme